Scarica l'app Stockscreener
42.23
5.29%
2.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$40.11
Aprire:
$41.85
Volume 24 ore:
16.32M
Relative Volume:
1.42
Capitalizzazione di mercato:
$16.50B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-4.8373
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+2.97%
1M Prestazione:
+6.64%
6M Prestazione:
+57.05%
1 anno Prestazione:
+32.30%
Intervallo 1D:
$41.20
$44.80
Intervallo di 1 settimana:
$36.66
$45.50
Portata 52W:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
42.23 | 15.67B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Barclays starts Moderna, Inc. (MRNA) neutral as biotech outlook improves - MSN
CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot - The Cancer Letter
Moderna CEO Worries About Drug Development Overall After US FDA mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna looks outside US for growth after FDA’s flu shot refusal - whbl.com
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results - FinancialContent
Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend - FXEmpire
Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. - Barron's
Moderna Has A Few Words For The FDA After mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Moderna: Q4 Earnings Snapshot - theheraldreview.com
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial Challenges - GuruFocus
Moderna (MRNA) Faces Challenges Amid Renewed Interest in Biotech Sector - GuruFocus
Moderna Challenges FDA After Flu Shot Review Refusal, 26% Covid Drop - GuruFocus
Market movers: Moderna, Pinterest, DraftKings, Coinbase, Immunic... - Proactive financial news
Moderna's mRNA Technology Has Potential Across Vaccines, Oncology, and Rare Diseases - Morningstar
Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results, Beats Estimates By $0.68 EPS - MarketBeat
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates - The Desert Sun
Moderna Reports 4Q Revenue Of $678 Million, Projects 2026 Growth - AlphaStreet News
Moderna shares jump as company affirms growth outlook - BioPharma Dive
Moderna shares pop on strong guidance, smaller-than-expected loss - Yahoo Finance
Pink Sheet Podcast: US FDA Versus Moderna And The Changing Role Of Refuse To File Actions - Citeline News & Insights
Moderna climbs 11% after Q4 revenue beats estimates - breakingthenews.net
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates - Nasdaq
FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’ - The Guardian
Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation - BioSpace
Moderna beats Q4 revenue estimate - BNN Bloomberg
Moderna (MRNA) Shares Rise Despite FDA Rejection of Flu Vaccine Application - GuruFocus
Moderna tops Q4 2025 EPS by 51c, beats on revenue - The Pharma Letter
Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms - Benzinga
Moderna (NASDAQ:MRNA) Trading 7.2% Higher Following Better-Than-Expected Earnings - MarketBeat
Moderna Maintains Full-Year Revenue Growth Outlook Following Fourth-Quarter Beat - marketscreener.com
Moderna Q4 Earnings Call Highlights - MarketBeat
Moderna Shares Rise After Q4 Loss Narrows, Revenue Beats Estimates - marketscreener.com
Softer-Than-Expected Inflation Sparks Rally In These 10 Stocks - Benzinga
Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, and More Movers - Barron's
Moderna Q4 2025 slides reveal strategic pivot as losses narrow, shares climb - Investing.com
Moderna Sales Beat as Covid Shot Demand Falls Less Than Expected - Bloomberg.com
Earnings call transcript: Moderna’s Q4 2025 results exceed expectations - Investing.com
Moderna Reiterates 10% Revenue-Growth Target as Covid Vaccine Demand Falls - The Wall Street Journal
Moderna Reiterates 10% Revenue-Growth Target as Covid Vaccine Demand Falls -- Update - marketscreener.com
Moderna Q4 Loss Narrows - Nasdaq
AI for investors - MLQ.ai
Moderna beats quarterly revenue estimates on resilient COVID shot sales - BNN Bloomberg
A Political Appointee Overruled FDA Scientists to Block Moderna's Flu Vaccine — and the Fallout Is Just Beginning - WebProNews
Applied Materials, Arista, Moderna, Coinbase, DraftKings, Steel Dynamics, Rivian, Roku, and More Movers - Barron's
Moderna Just Crushed Estimates While Everyone Was Looking the Other Way - 24/7 Wall St.
Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Moderna (MRNA) Surpasses Q4 Earnings Expectations Despite Revenue Decline - GuruFocus
Moderna (MRNA) Q4 2025 Earnings Call Transcript - The Globe and Mail
Moderna Narrows Loss, Reiterates 10% Revenue Growth Target - The Wall Street Journal
Moderna beats quarterly revenue estimates on resilient sales of COVID shot - marketscreener.com
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):